SLU-PP-332 vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Recovery & Repair
Larazotide Acetate- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- Local gut action; minimal systemic exposure
- Admin Route
- Oral (research), Subcutaneous (research)
- Oral
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 0.5-2 mg
- Frequency
- Once daily in rodent studies
- 3x daily
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —